A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke

Teal, Philip;Davis, Stephen;Hacke, Werner;Kaste, Markku;Peeters, André;et.al.
(2009) Stroke : a journal of cerebral circulation — Vol. 40, n° 11, p. 3518-3525 (2009)

Files

2009-mRECTStroke.pdf
  • Open Access
  • Adobe PDF
  • 261.75 KB
Download

Details

Authors
  • Teal, Philip
    Author
  • Davis, Stephen
    Author
  • Hacke, Werner
    Author
  • Kaste, Markku
    Author
  • Peeters, AndréUCLouvain
    Collaborator
Show more
Abstract
mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test to achieve a targeted exposure to repinotan. The study failed to demonstrate a clinical benefit of repinotan. The development of repinotan in acute ischemic stroke was discontinued.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Teal, P., Davis, S., Hacke, W., Kaste, M., Lyden, P. D., & Fierus, M. (2009). A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke. Stroke : a journal of cerebral circulation, 40(11), 3518-3525. https://doi.org/10.1161/STROKEAHA.109.551382 (Original work published 2009)